Concepedia

Peter C. Rüegg

PC

Statistics

Publications

4

Citations

151

H-Index

4

Active since

1989

Affiliations

Novartis (Switzerland)(Current)

Peter C. Rüegg is an author at Novartis (Switzerland) specializing in pharmacotherapy, hypertension, and cardiovascular disease.

Top concepts

Publications per year

1989–2005

4

Publications

4

Tegaserod, a 5-hydroxytryptamine type 4 receptor partial agonist, is devoid of electrocardiographic effects

Joel Morganroth, Peter C. Rüegg, Cornelia Dunger‐Baldauf et al. · The American Journal of Gastroenterology · 2002 · 70 citations

Safety and tolerability of tegaserod in patients with irritable bowel syndrome and diarrhea symptoms

James Fidelholtz, William Smith, James Rawls et al. · The American Journal of Gastroenterology · 2002 · 37 citations

A multicenter evaluation of the safety, tolerability, and efficacy of isradipine in the treatment of essential hypertension

Carl‐David Sundstedt, Peter C. Rüegg, Annemarie Keller et al. · The American Journal of Medicine · 1989 · 25 citations

, , +11

Tegaserod: Long-Term Treatment for Irritable Bowel Syndrome Patients with Constipation in Primary Care

Peter Layer, Jutta Keller, Stefan Mueller‐Lissner et al. · Digestion · 2005 · 19 citations

1–4 of 4